180 Life Sciences (NASDAQ: ATNF)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-15 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.050 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of 180 Life Sciences (NASDAQ: ATNF) through any online brokerage.
Other companies in 180 Life Sciences’s space includes: Vincerx Pharma (NASDAQ:VINC), Cabaletta Bio (NASDAQ:CABA), Cellectar Biosciences (NASDAQ:CLRB), T2 Biosystems (NASDAQ:TTOO) and Monopar Therapeutics (NASDAQ:MNPR).
The latest price target for 180 Life Sciences (NASDAQ: ATNF) was reported by Maxim Group on Monday, May 9, 2022. The analyst firm set a price target for 0.00 expecting ATNF to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.
The stock price for 180 Life Sciences (NASDAQ: ATNF) is $0.9153 last updated June 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for 180 Life Sciences.
180 Life Sciences’s Q2 earnings are confirmed for Monday, August 15, 2022.
There is no upcoming split for 180 Life Sciences.
180 Life Sciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.